These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22119063)

  • 1. Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial.
    Hirohata A; Yamamoto K; Miyoshi T; Hatanaka K; Hirohata S; Yamawaki H; Komatsubara I; Hirose E; Kobayashi Y; Ohkawa K; Ohara M; Takafuji H; Sano F; Toyama Y; Kusachi S; Ohe T; Ito H
    Atherosclerosis; 2012 Jan; 220(1):134-8. PubMed ID: 22119063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial.
    Hirohata A; Yamamoto K; Miyoshi T; Hatanaka K; Hirohata S; Yamawaki H; Komatsubara I; Murakami M; Hirose E; Sato S; Ohkawa K; Ishizawa M; Yamaji H; Kawamura H; Kusachi S; Murakami T; Hina K; Ohe T
    J Am Coll Cardiol; 2010 Mar; 55(10):976-82. PubMed ID: 20202514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the OLIVUS trial.
    Miyoshi T; Hirohata A; Usui S; Yamamoto K; Murakami T; Komatsubara I; Kusachi S; Ohe T; Nakamura K; Ito H
    Heart Vessels; 2014 Mar; 29(2):178-85. PubMed ID: 23563752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of angiotensin II receptor blocker therapy (olmesartan or valsartan) on coronary atherosclerotic plaque volume measured by intravascular ultrasound in patients with stable angina pectoris.
    Ishii H; Kobayashi M; Kurebayashi N; Yoshikawa D; Suzuki S; Ichimiya S; Kanashiro M; Sone T; Tsuboi H; Amano T; Uetani T; Harada K; Marui N; Murohara T
    Am J Cardiol; 2013 Aug; 112(3):363-8. PubMed ID: 23623047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of intravascular ultrasound imaging on early and late clinical outcomes following percutaneous coronary intervention with drug-eluting stents.
    Claessen BE; Mehran R; Mintz GS; Weisz G; Leon MB; Dogan O; de Ribamar Costa J; Stone GW; Apostolidou I; Morales A; Chantziara V; Syros G; Sanidas E; Xu K; Tijssen JG; Henriques JP; Piek JJ; Moses JW; Maehara A; Dangas GD
    JACC Cardiovasc Interv; 2011 Sep; 4(9):974-81. PubMed ID: 21939937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gender and the extent of coronary atherosclerosis, plaque composition, and clinical outcomes in acute coronary syndromes.
    Lansky AJ; Ng VG; Maehara A; Weisz G; Lerman A; Mintz GS; De Bruyne B; Farhat N; Niess G; Jankovic I; Lazar D; Xu K; Fahy M; Serruys PW; Stone GW
    JACC Cardiovasc Imaging; 2012 Mar; 5(3 Suppl):S62-72. PubMed ID: 22421232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound from the Japanese assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) trial.
    Hibi K; Kimura T; Kimura K; Morimoto T; Hiro T; Miyauchi K; Nakagawa Y; Yamagishi M; Ozaki Y; Saito S; Yamaguchi T; Daida H; Matsuzaki M;
    Atherosclerosis; 2011 Dec; 219(2):743-9. PubMed ID: 21899843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS.
    Puri R; Nissen SE; Menon V; Shao M; Hsu A; Bakris GL; Kastelein JJ; Williams B; Armbrecht J; Brunel P; Kataoka Y; Nicholls SJ
    Atherosclerosis; 2015 Dec; 243(2):553-9. PubMed ID: 26523993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary plaque progression of non-culprit lesions after culprit percutaneous coronary intervention in patients with moderate to advanced chronic kidney disease: intravascular ultrasound and integrated backscatter intravascular ultrasound study.
    Kashiyama K; Sonoda S; Muraoka Y; Suzuki Y; Kamezaki F; Tsuda Y; Araki M; Tamura M; Takeuchi M; Abe H; Okazaki M; Fujino Y; Otsuji Y
    Int J Cardiovasc Imaging; 2015 Jun; 31(5):935-45. PubMed ID: 25724567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.
    Yano H; Hibi K; Nozawa N; Ozaki H; Kusama I; Ebina T; Kosuge M; Tsukahara K; Okuda J; Morita S; Umemura S; Kimura K
    Circ J; 2012; 76(6):1442-51. PubMed ID: 22473458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of percutaneous coronary intervention in intermediate coronary artery disease: fractional flow reserve-guided versus intravascular ultrasound-guided.
    Nam CW; Yoon HJ; Cho YK; Park HS; Kim H; Hur SH; Kim YN; Chung IS; Koo BK; Tahk SJ; Fearon WF; Kim KB
    JACC Cardiovasc Interv; 2010 Aug; 3(8):812-7. PubMed ID: 20723852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residual plaque burden in patients with acute coronary syndromes after successful percutaneous coronary intervention.
    McPherson JA; Maehara A; Weisz G; Mintz GS; Cristea E; Mehran R; Foster M; Verheye S; Rabbani L; Xu K; Fahy M; Templin B; Zhang Z; Lansky AJ; de Bruyne B; Serruys PW; Stone GW
    JACC Cardiovasc Imaging; 2012 Mar; 5(3 Suppl):S76-85. PubMed ID: 22421234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plaque burden with composition? That is the next question.
    Marso SP
    J Am Coll Cardiol; 2010 Mar; 55(10):983-5. PubMed ID: 20202515
    [No Abstract]   [Full Text] [Related]  

  • 15. A global risk approach to identify patients with left main or 3-vessel disease who could safely and efficaciously be treated with percutaneous coronary intervention: the SYNTAX Trial at 3 years.
    Serruys PW; Farooq V; Vranckx P; Girasis C; Brugaletta S; Garcia-Garcia HM; Holmes DR; Kappetein AP; Mack MJ; Feldman T; Morice MC; Ståhle E; James S; Colombo A; Pereda P; Huang J; Morel MA; Van Es GA; Dawkins KD; Mohr FW; Steyerberg EW
    JACC Cardiovasc Interv; 2012 Jun; 5(6):606-17. PubMed ID: 22721655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes.
    Marso SP; Mercado N; Maehara A; Weisz G; Mintz GS; McPherson J; Schiele F; Dudek D; Fahy M; Xu K; Lansky A; Templin B; Zhang Z; de Bruyne B; Serruys PW; Stone GW
    JACC Cardiovasc Imaging; 2012 Mar; 5(3 Suppl):S42-52. PubMed ID: 22421230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of angiographic and intravascular ultrasound features on clinical outcome after sirolimus-eluting stent implantation for de-novo lesions in nondiabetic and type 2 diabetic patients.
    Du R; Zhang RY; Zhu ZB; Zhang Q; Hu J; Yang ZK; Yan ZJ; Lv AK; Ding FH; Zhang JS; Shen WF
    Coron Artery Dis; 2010 May; 21(3):175-81. PubMed ID: 20305549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.
    Mason RP
    Vasc Health Risk Manag; 2011; 7():405-16. PubMed ID: 21796255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between IVUS findings and adverse outcomes in patients with coronary artery disease: the VIVA (VH-IVUS in Vulnerable Atherosclerosis) Study.
    Calvert PA; Obaid DR; O'Sullivan M; Shapiro LM; McNab D; Densem CG; Schofield PM; Braganza D; Clarke SC; Ray KK; West NE; Bennett MR
    JACC Cardiovasc Imaging; 2011 Aug; 4(8):894-901. PubMed ID: 21835382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term health outcome and mortality evaluation after invasive coronary treatment using drug eluting stents with or without the IVUS guidance. Randomized control trial. HOME DES IVUS.
    Jakabcin J; Spacek R; Bystron M; Kvasnák M; Jager J; Veselka J; Kala P; Cervinka P
    Catheter Cardiovasc Interv; 2010 Mar; 75(4):578-83. PubMed ID: 19902491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.